Case Reports in Infectious Diseases
Volume 2018 (2018), Article ID 3106305, 3 pages
https://doi.org/10.1155/2018/3106305

Case Report

Methicillin-Resistant Staphylococcus aureus as a Probable Cause of Antibiotic-Associated Enterocolitis

Alison B. Lane,¹ Nathanial K. Copeland,¹ Fatma Onmus-Leone,² and James V. Lawler1,3

¹Department of Medicine, Division of Infectious Diseases, Walter Reed National Military Medical Center, Bethesda, MD, USA
²Multidrug-Resistant Organism Repository and Surveillance Network, Walter Reed Army Institute of Research, Silver Spring, MD, USA
³Naval Medical Research Center, Frederick, MD, USA

Correspondence should be addressed to Alison B. Lane; alison.b.lane.mil@mail.mil

Received 15 March 2018; Accepted 28 June 2018; Published 5 August 2018

Academic Editor: Gernot Walder

Copyright © 2018 Alison B. Lane et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Antibiotic-associated diarrhea is typically associated with Clostridium difficile. However, Staphylococcus aureus has also been described as a cause of antibiotic-associated enterocolitis and diarrhea and is likely an underrecognized etiology. We present a case of enterocolitis and urinary tract infection caused by methicillin-resistant S. aureus following antibiotic treatment.

1. Introduction

The most commonly identified pathogen in healthcare-associated diarrhea is Clostridium difficile, particularly in the setting of antibiotic use [1]. However, prior to the identification of C. difficile and its toxins as contributors to healthcare-associated diarrhea in the mid-1970s, Staphylococcus aureus was recognized as a causative agent of antibiotic-associated enterocolitis (AAE). Staphylococcal enterocolitis was first described in the 1950s, but increasing prevalence of C. difficile in recent years has led to underrecognition of S. aureus as an etiology of nosocomial and antibiotic-associated diarrhea [1]. We present a case of enterocolitis and urinary tract infection caused by methicillin-resistant S. aureus (MRSA) following antibiotic treatment in a MRSA-colonized patient.

2. Case

An 87-year-old woman presented to the emergency department with three days of abdominal pain, nausea, vomiting, and copious diarrhea. She described watery stools occurring up to eight times each day, without blood or mucus. She reported fatigue and anorexia but denied fevers and chills, as well as dysuria or other urinary symptoms. Six days previously, she had been discharged after a week-long hospitalization for ST-elevation myocardial infarction, which included diagnostic cardiac catheterization via femoral access. During this hospitalization, she was also diagnosed with community-acquired pneumonia and was started on intravenous ceftriaxone and azithromycin, with transition to oral levofloxacin at discharge.

On initial examination, she was afebrile with heart rate of 91 and blood pressure 95/48 (slightly below her outpatient baseline). Oral mucosae were dry and abdomen was soft, nondistended and diffusely tender without peritoneal signs, suprapubic tenderness, or costovertebral angle tenderness. Initial labs revealed a neutrophil-predominant leukocytosis of 15,800 cells/µL; creatinine 1.31 mg/dL (previous baseline 0.65 mg/dL); and normal lactate, liver-associated enzymes, and lipase. Urinalysis demonstrated positive leukocyte esterase, 34 leukocytes/hpf, and negative nitrite. Fecal leukocytes and C. difficile PCR (Cepheid® Xpert® C. difficile) were negative. Abdominal plain films were unremarkable.

The patient was admitted for fluid resuscitation and symptomatic management with ondansetron and loperamide, with improvement of her abdominal pain and nausea. However, her profuse diarrhea persisted, and on hospital day 2, both urine and stool cultures obtained on admission grew MRSA. Abdominal CT revealed sigmoid bowel wall thickening consistent with colitis. The patient was started on vancomycin via both intravenous (750 mg daily) and oral (125 mg every 6 hours) routes with significant improvement of her diarrhea the following day. Though blood cultures remained negative, given her multifocal MRSA in the setting of recent femoral catheterization and history of rheumatic heart disease, she underwent transesophageal echocardiography which showed no evidence of endocarditis. She finished 10 days of oral and 14 days of parenteral vancomycin and recovered completely.

Due to the overwhelming predominance of MRSA in the stool culture and concomitant presence in the urine, isolates from both sources underwent genotyping with whole-genome sequencing. DNA was extracted and then sequenced using MiSeq Reagent Kit v3 (Illumina, San Diego, CA, USA). Sequencing reads were assembled, and comparative genomic analyses were performed using Geneious (Biomatters, Auckland, New Zealand) [2]. The isolates were found to be genetically identical and shared several genes potentially involved in pathogenesis (Table 1). Notably, the staphylococcal enterotoxin B (seb) gene and precursor gene for staphylococcal enterotoxin D (entD) were present.

Table 1: Putative and confirmed virulence and toxin genes and associated proteins detected in both MRSA isolates.

Clinically relevant downstream effects

Toxin genes

    entDa, seba
Staphylococcal enterotoxins (SE-B and D) which act as superantigens

    hla, hld, hlgA, hlgB, hlgC
Cytotoxins

Virulence genes

    aur, cap8A, cap8B, cap8C, cap8D, cap8F, cap8G,     cap8L, cap8N, cap8M, cap8O, chp, geh, sbi, scn,     sspB, sspC
Disruption of host complement activity, phagocytosis, and/or immune cell chemotaxis

    ebpS, fnb, sdrC
Host tissue adherence

    esaA, esaB, esaC, essB, essC, esxA, esxB
Virulence proteins via unclear mechanisms, perhaps modulate host cell apoptosis

    hysA, sak
Tissue degradation and invasion

    icaA, icaB, icaR
Biofilm formation

    isdA, isdB, isdD, isdF, isdG
Iron acquisition

    MW0023
Immune modulation

    srtB
Modification of bacterial surface proteins

    sspA
Modification of bacterial enzymes and cleavage of immunoglobulin G

aPreviously demonstrated in cases of MRSA antibiotic-associated enterocolitis.

3. Discussion

While MRSA is well-recognized as an important and serious nosocomial and community-acquired pathogen, its role as a causative agent of AAE is less established in recent Western literature. AAE caused by enterotoxin-producing staphylococci was initially described in the 1950s [3, 4]. However, in 1978, Clostridium difficile and its toxins were identified as the principle causative agents of post-antibiotic pseudomembranous colitis (S. aureus was also seen, though accounted for a minority of cases) [5, 6]. Since that time, authors have only rarely reported cases of MRSA AAE, with more cases published in Japanese [7] compared to Western literature [8]. However, a prospective study of stools negative for C. difficile toxin from patients with diarrhea found MRSA in 13 out of 3210 stool specimens, with 11 isolates producing staphylococcal enterotoxins [9]. Recently, Iwata et al. conducted a comprehensive review of the literature related to MRSA AAE and identified nine criteria that support a causative relationship [10]. It is therefore possible that MRSA constitutes an underappreciated cause of AAE [11].

Similar to C. difficile infection, risk factors for development of MRSA AAE include advanced age, immunosuppression, prolonged hospital stays, and previous antibiotic treatment [12, 13]. For MRSA in particular, prior fluoroquinolone use (as in our patient) is associated with an increased risk [12]. Though MRSA AAE can have a very similar clinical presentation to C. difficile, it is more likely to involve the small intestine instead of cecum or colon, and can result in localized bowel wall thickening on CT, as seen in this case [9, 13, 14]. Diarrhea is typically profuse, large volume, and watery, and patients with MRSA colitis are more likely to have associated symptoms of nausea, vomiting, and fever [13].

Similar to the pathogenesis of C. difficile, MRSA enterocolitis is likely caused by a toxin-mediated mechanism. More than 20 different staphylococcal enterotoxins (SEs) have been identified [15]. Many have well-understood roles in staphylococcal food poisoning, and several reports have identified TSST-1 as well as SE-A, B, C, D, and E in cases of S. aureus enterocolitis [7, 9, 10, 12]. Staphylococcal leucocidin LukE-LukD also has proposed involvement in the disease process via a cytotoxic mechanism, and in one case, series was identified in 94% of MRSA enterocolitis isolates [16]. The majority of MRSA are toxin-producing strains, which may account for their relative prevalence (in comparison with MSSA) in cases of enterocolitis [15].

In cases of severe antibiotic-associated diarrhea when C. difficile toxin testing is negative, stool culture should be performed for further evaluation, and isolation of MRSA as the predominant organism should suggest causation. Testing for viral enteric pathogens (though not performed in this case) is now more widely available, and these should also be excluded. When MRSA is identified or suspected as the cause of antibiotic-associated colitis, oral vancomycin is the recommended treatment [12]. While diarrheal symptoms often begin to resolve within 24 hours of initiation of vancomycin, typically a 10–14-day course of 125–250 mg daily is used to ensure adequate treatment, though data on exact dose and duration are sparse and warrant further study [12, 17]. Additionally, supportive care and symptomatic management are important, and as diarrhea tends to be very profuse, aggressive fluid resuscitation is often necessary.

Though C. difficile is the most common infectious cause of antibiotic-associated diarrhea, MRSA is a clinically relevant and likely underdiagnosed etiology. Our patient’s presentation with colitis following a recent course of antibiotics, negative C. difficile PCR, MRSA overgrowth on stool cultures to the exclusion of normal fecal flora, and rapid resolution of diarrhea following initiation of oral vancomycin was consistent with MRSA as the inciting pathogen.

Disclosure

The views expressed in this manuscript are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of the Army, Department of Defense, nor the U.S. Government.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

D. N. Gerding and V. B. Young, “Clostridium difficile infection,” in Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, Saunders, Philadelphia, PA, USA, 8th edition, 2015.

M. Kearse, R. Moir, A. Wilson et al., “Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data,” Bioinformatics, vol. 28, no. 12, pp. 1647–1649, 2012.

G. S. Speare, “Staphylococcus pseudomembranous enterocolitis, a complication of antibiotic therapy,” American Journal of Surgery, vol. 88, no. 4, pp. 523-524, 1954.

M. J. Surgalla and G. M. Dack, “Enterotoxin produced by micrococci from cases of enteritis after antibiotic therapy,” Journal of the American Medical Association, vol. 158, no. 8, pp. 649-650, 1955.

J. G. Bartlett, T. W. Chang, M. Gurwith, S. L. Gorbach, and A. B. Onderdonk, “Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia,” New England Journal of Medicine, vol. 298, no. 10, pp. 531–534, 1978.

H. E. Larson, A. B. Price, P. Honour, and S. P. Borriello, “Clostridium difficile and the aetiology of pseudomembranous colitis,” The Lancet, vol. 1, pp. 1063–1066, 1978.

Y. Ogawa, T. Saraya, T. Koide et al., “Methicillin-resistant Staphylococcus aureus enterocolitis sequentially complicated with septic arthritis: a case report and review of the literature,” BMC Research Notes, vol. 7, no. 1, pp. 21–27, 2014.

A. Kalakonda, S. Garg, S. Tandon, R. Vinayak, and S. Dutta, “A rare case of infectious colitis,” Gastroenterology Report, vol. 4, no. 4, 2015.

J. M. Boyce and N. L. Havill, “Nosocomial antibiotic-associated diarrhea associated with enterotoxin-producing strains of methicillin-resistant Staphylococcus aureus,” American Journal of Gastroenterology, vol. 100, no. 8, pp. 1828–1834, 2005.

K. Iwata, A. Doi, T. Fukuchi et al., “A systematic review for pursuing the presence of antibiotic associated enterocolitis caused by methicillin resistant Staphylococcus aureus,” BMC Infectious Diseases, vol. 14, pp. 247–259, 2014.

K. Clarke and L. Baidoo, “Methicillin-resistant Staphylococcus aureus (MRSA) colitis–is there a problem?” International Journal of Colorectal Disease, vol. 27, no. 3, pp. 417-418, 2012.

Z. Lin, D. P. Kotler, P. M. Schlievert, and E. M. Sordillo, “Staphylococcal enterocolitis: forgotten but not gone?” Digestive Diseases and Sciences, vol. 55, no. 5, pp. 1200–1207, 2010.

G. Gorkiewicz, “Nosocomial and antibiotic-associated diarrhoea caused by organisms other than Clostridium difficile,” International Journal of Antimicrobial Agents, vol. 33, pp. S37–S41, 2009.

M. K. Froberg, E. Palavecino, R. Dykoski, D. N. Gerding, L. R. Peterson, and S. Johnson, “Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases,” Clinical Infectious Diseases, vol. 39, pp. 747–750, 2004.

I. V. Pinchuk, E. J. Beswick, and V. E. Reyes, “Staphylococcal enterotoxins,” Toxins, vol. 2, no. 8, pp. 2177–2197, 2010.

A. Gravet, M. Rondeau, C. Harf-Monteil et al., “Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD,” Journal of Clinical Microbiology, vol. 37, pp. 4012–4019, 1999.

E. N. Sizemore, K. M. Rivas, J. Valdes, and J. Caballero, “Enteral vancomycin and probiotic use for methicillin-resistant Staphylococcus aureus antibiotic-associated diarrhoea,” BMJ Case Reports, vol. 2012, Article ID bcr2012006366, 2012.